Immunome Inc., a biotechnology company specializing in targeted cancer therapies, announced on July 1, 2025, that its Compensation Committee granted inducement awards in the form of non-statutory stock options to eight new employees. These options are part of the Company's 2024 Inducement Plan and involve a total of 125,500 shares of common stock. Each stock option is priced at $8.47 per share, reflecting the closing sales price on the grant date. The vesting schedule requires 25% of the shares to vest after one year, with the remaining shares vesting monthly over the following 36 months, contingent on the employees' ongoing service with the company.